Regeneron Pharmaceuticals, Inc. (REGN) 当前追踪市盈率 (P/E) 为 17.6, 前瞻市盈率为 16.7. 追踪盈利收益率为 5.67%, 前瞻盈利收益率 6.00%. PEG 2.15. 格雷厄姆数为 $547.01.
本页证实的标准:
SharesGrow 综合评分： 83/100 其中 6/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | 47.7 | 1.24 | 9.59 | 8.78 | - |
| 2017 | 36.4 | 1.14 | 7.09 | 7.42 | - |
| 2018 | 17.5 | 0.20 | 4.90 | 6.39 | - |
| 2019 | 19.4 | -2.16 | 3.70 | 6.25 | - |
| 2020 | 14.8 | 0.22 | 4.71 | 6.12 | - |
| 2021 | 8.3 | 0.06 | 3.56 | 4.15 | - |
| 2022 | 17.8 | -0.38 | 3.41 | 6.35 | - |
| 2023 | 23.7 | -2.78 | 3.61 | 7.14 | - |
| 2024 | 17.4 | 1.68 | 2.62 | 5.41 | - |
| 2025 | 17.9 | 3.38 | 2.58 | 5.63 | 0.46% |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $7.70 | $4.86B | $895.52M | 18.4% |
| 2017 | $10.34 | $5.87B | $1.2B | 20.4% |
| 2018 | $21.29 | $6.71B | $2.44B | 36.4% |
| 2019 | $18.46 | $7.86B | $2.12B | 26.9% |
| 2020 | $30.52 | $8.5B | $3.51B | 41.3% |
| 2021 | $71.97 | $16.07B | $8.08B | 50.2% |
| 2022 | $38.22 | $12.17B | $4.34B | 35.6% |
| 2023 | $34.77 | $13.12B | $3.95B | 30.1% |
| 2024 | $38.34 | $14.2B | $4.41B | 31.1% |
| 2025 | $41.48 | $14.34B | $4.5B | 31.4% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $45.38 | $33.43 – $51.52 | $15.7B | $14.74B – $16.36B | 16 |
| 2027 | $52.94 | $29.88 – $66.84 | $17.32B | $16.14B – $19.07B | 8 |
| 2028 | $60.83 | $49.47 – $73.09 | $18.7B | $18.66B – $18.73B | 8 |
| 2029 | $67.38 | $60.61 – $74.35 | $20.18B | $18.62B – $21.78B | 6 |
| 2030 | $71.97 | $64.73 – $79.42 | $21.24B | $19.59B – $22.93B | 6 |
